Mutations in the SF3B1 gene were found in about 10–15% of CLL and correlate with deletions of 11q22 and ATM mutations, a poor prognosis, and resistance to fludarabine therapy [56,57,58]; nevertheless, there is no correlation between SF3B1 and IGHV mutational status [59]. This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.